Home » Stocks » IPA

ImmunoPrecise Antibodies Ltd. (IPA)

Stock Price: $6.81 USD -0.35 (-4.89%)
Updated May 12, 2021 3:59 PM EDT - Market closed
Market Cap 133.62M
Revenue (ttm) 17.18M
Net Income (ttm) n/a
Shares Out 19.08M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $6.81
Previous Close $7.16
Change ($) -0.35
Change (%) -4.89%
Day's Open 7.00
Day's Range 6.81 - 7.36
Day's Volume 64,822
52-Week Range 6.64 - 33.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

3 weeks ago - Business Wire

ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate char...

1 month ago - Benzinga

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

1 month ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

1 month ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

1 month ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

1 month ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery...

2 months ago - Business Wire

ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) announces preliminary preclinical data of TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In the SARS-Co...

2 months ago - Benzinga

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamster...

2 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery...

4 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced ...

4 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("Company" or "IPA") (TSXV: IPA) (Nasdaq: IPA), a leader in full-service, therapeutic antibody discovery and development, today...

Other stocks mentioned: IPATF
4 months ago - Business Wire

VICTORIA, BC, Nov. 3, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and deve...

Other stocks mentioned: IPATF
6 months ago - PRNewsWire

Developing Antibodies for Covid-19

YouTube video

Sep.28 -- Jennifer Bath, chief executive officer at Immunoprecise Antibodies Ltd., discusses the company's potentially groundbreaking Covid-19 antibody treatment on "Bloomberg Technology.

Other stocks mentioned: IPATF
7 months ago - Bloomberg Technology

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production an... [Read more...]

Industry
Biotechnology
IPO Date
Jan 3, 2017
Stock Exchange
NASDAQ
Ticker Symbol
IPA
Full Company Profile

Financial Performance

In 2020, IPA's revenue was 14.06 million, an increase of 28.66% compared to the previous year's 10.93 million. Losses were -4.95 million, -35.05% less than in 2019.

Financial numbers in millions CAD.
Financial Statements